Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case Report

Severe stroke in patients admitted to intensive care unit after COVID-19 infection: Pictorial essay of a case series

Cristian Deana a,⇑, Daniele Bagatto b

a Department of Anesthesia and Intensive Care, Health Integrated Agency of Friuli Centrale, Udine, Italy
b Department of Neuroradiology, Health Integrated Agency of Friuli Centrale, Udine, Italy

Abstract

Patients infected by COVID-19 could require intensive care unit admission especially due to acute respiratory failure. However, neurological manifestations are very common. Among these, ischemic stroke or cerebral hemorrhage may have unfavorable outcome. The mechanisms leading to cerebral damage by SARS-CoV2 are still under debate. One of the most accepted theories implies an endothelial activation which in turns increase the risk of thrombus formation with the development of stroke, either ischemic or hemorrhagic. The more severe the COVID-19 disease, the higher the risk of stroke. Stroke in ICU patients are not frequent, but cerebral hemorrhage has devastating effects with high mortality. In these pictorial essay of case reports, main clinical aspects are discussed, along with a summary of the evidence about pathophysiology and treatment of these patients.

1. Introduction

COVID-19 started at the end of 2019 in Wuhan, China, and then spread worldwide. There have been many waves of infections. At the time of writing, some countries are experiencing a fifth.1 The COVID-19 pandemic has put national health systems under stress, especially in terms of patient admittance, mostly for severe cases requiring intensive care unit (ICU) beds.2 Unfortunately, ICU bed availability has not always been able to meet demand, leading to unintentional deaths outside ICUs.3

The reason for ICU admittance for COVID-19 patients is severe acute respiratory failure. Neurological involvement has been frequently reported, however, the main symptoms of which are anosmia, dysgeusia, headache, mental confusion and seizures.4 Stroke is another cerebral complication of COVID-19, placing patients at risk of loss of life. The treatment of stroke complications also entails some logistical aspects, such as a dedicated COVID-team.5

Neurological manifestations of COVID-19 have been extensively studied, and various theories have been put forward to explain the behavioral changes.6

In the ICU, patients with severe acute respiratory failure require sedation for mechanical ventilation. Neurological evaluation thus becomes difficult, especially for deeply sedated patients, with the consequence that some neurological signs and symptoms can be missed.7

Critical care physicians have seen an increase in the number of patients with acute stroke related to severe COVID-19 infection [8]. These should be taken into consideration as long as the COVID-19 pandemic continues, not only in patients with a severe manifestation of viral infection but also in those experiencing mild SARS-CoV2 symptoms.9

This pictorial review presents five case reports describing the different possible manifestations of stroke in critically ill patients infected with SARS-CoV2, diagnosed with real-time PCR on nasopharyngeal swabs. A summary of the main pathophysiological and treatment aspects is also provided.

Table 1 summarizes the main features of the case reports.

Since only anonymous data are included in this work, the requirement for an Ethics Committee was waived. General informed consent for publication was obtained whenever possible.

2. Case report #1

A 45-year-old woman was admitted to the emergency department (ED) of a spoke center due to disartria. She had been complaining of headaches in the previous days. Forty-two days prior...
to hospital admittance, she had tested positive for COVID-19 (real-time PCR nasal swab) and had suffered a mild case of anosmia. Her past medical history was unremarkable.

An immediate head computed tomography (CT) scan revealed cerebral venous thrombosis with a small hemorrhagic focus in the left temporal lobe (Fig. 1A–B–C). She was then transferred to the hub center where she underwent endotracheal intubation due to her reduced level of consciousness. In the meantime, unfractioned heparin infusion was commenced as the first line treatment. After four days of unfractioned heparin, the patient’s therapy was switched to enoxaparin 4000 bid.

After four days of unfractioned heparin, the patient’s therapy was switched to enoxaparin 6000 international units (IU) every 12 h. At day 12, a tracheostomy was performed due to the slow recovery of consciousness and a concomitant need for mechanical ventilation for ventilator-associated pneumonia. The patient was transferred to the neurology unit at day 20, and to a rehabilitation unit at day 36. She was finally discharged at day 12 h. At day 12, a tracheostomy was performed due to the slow recovery of consciousness and a concomitant need for mechanical ventilation for ventilator-associated pneumonia. The patient was transferred to the neurology unit at day 20, and to a rehabilitation unit at day 36. She was finally discharged at day 36.

### 3. Case report #2

A 55-year-old man with a history of arterial hypertension and psoriasis was admitted to the ED due to worsening headache, nausea, diplopia and postural instability. Glasgow coma scale was measured at 15. Forty-five days prior to this visit, the patient presented with a mild COVID-19 infection (cold-like symptoms with no respiratory involvement).

An immediate CT head scan revealed a basilar thrombosis (Fig. 2A–B). The patient underwent an angiographic endovascular procedure that reperfused the arterial vessels. However, partial thrombosis at the vertebra-basilar junction persisted. The onset of sudden coma (GCS 3 immediately following angiography) meant that the patient required intubation and mechanical ventilation. He was admitted to the ICU.

After 24 h, a CT-scan revealed a large cerebellar ischemia and hypodensity at the level of the brainstem and thalami. After seven days, the patient was declared brain dead.
and at day 20 he was transferred to the neurology unit. Finally, at day 37, he was transferred to the general medicine ward, from where he was discharged to the rehabilitation unit. Neurological examination at hospital discharge revealed mild dysarthria, left facial paralysis (House Brackmann grade 3), plegia of the left arm and weakness of the left leg.

5. Case report #4

A previously healthy 46-year-old man was admitted to the ED due to the sudden onset of left hemiplegia after a headache. The patient tested positive for COVID-19. During admission, GCS decreased rapidly from 15 to 11. He was hence intubated and

Fig. 1. Axial non-enhanced computed tomography (NECT) showing a large and superficial hemorrhagic infarct involving the left temporal lobe (empty arrow in panel A). The axial and coronal reconstruction of the subsequent CT venography (CTV) examination revealed the presence of different filling defects inside the sigmoid sinus of the same side suggestive for dural sinus thrombosis (arrows in panel B and C).

Fig. 2. Axial NECT shows the “dense” artery sign in acute thrombosis of the basilar trunk (empty arrow, panel A) which is not visible and opacified (white arrow in panel B) in the coronal maximum intensity projection reconstruction of CT angiography (CTA) examination.
underwent a CT scan that showed a large right nucleo-capsular hemorrhage with mass effect on the brain (Fig. 4A). No surgical treatment was possible.

Blood exams revealed concomitant acute kidney injury (serum creatinine 6.33 mg/dL, blood urea nitrogen 63 mg/dL) and 3.5% of schistocytes and mild thrombocytopenia. Clinicians investigated whether uremic-hemolytic syndrome was the cause. The results of all tests performed (autoantibodies, microbiological and cultural samples) were negative.

After two days, transcranial coded color doppler (TCCD) at the bedside revealed impending cerebral circulatory arrest (Fig. 4B). The patient was diagnosed as brain dead the next day.

6. Case report #5

A 52-year-old man was admitted to the ICU due to coma. He had complained of fever two days previously. No illness was reported in his medical history. On the day of admission to the ICU, he was found unconscious at home with a GCS of 4, and vomiting. He was immediately intubated. After admittance to the ED, the patient tested positive for COVID-19.

A CT head scan revealed a subarachnoid hemorrhage (SAH) caused by a small aneurism of the right ophthalmic artery (Fig. 5A–B). At the same time, given his positive COVID-19 test and the high value of the D-dimer (see Table 1), the patient also underwent a CT thorax scan that revealed a pulmonary embolism (PE), but no lung involvement.

The patient never regained consciousness in the ICU, and developed a severe acute respiratory failure caused by SARS-CoV2 infection. He died after 17 days.

7. Discussion

Intracranial strokes associated with COVID-19 infection have been increasingly reported.10,11 Despite the increased risk of thrombotic events leading to an expected higher rate of acute ischemic stroke (AIS) among critically ill COVID-19 patients, a non-negligible number of hemorrhagic cerebral manifestations have been highlighted.12

COVID-19-associated AIS includes arterial thrombosis due to plaque rupture or embolization. Cases of cerebral vein sinuses thrombosis, which resembles deep vein thrombosis, have also been reported.13

Angiotensin converting enzyme 2 (ACE2) receptor, due to its presence in neuronal cells, seems to be an entry point to the brain for SARS-CoV-2, explaining neurological symptoms such as anosmia, dysgeusia and headache.14,15
However, the etiology of stroke in critically ill COVID-19 patients is probably multifactorial. It seems unlikely that direct cerebral nervous system (CNS) invasion by the virus leads to stroke. The elements of Virchow’s triad are blood stasis, endothelial injury and hypercoagulable state, and COVID-19 patients very frequently express all of these. Early on in the pandemic, clinical evidence appeared to support the prothrombotic state of these patients, as well as deep vein thrombosis and pulmonary embolism, especially in the moderate-severe cluster of infected people. Based on these findings, and results from autopsies highlighting a high rate of clinically silent PE, international guidelines recommend starting early with pharmacological venous thromboembolism (VTE) prophylaxis.

However, the above case reports also included patients who did not experience severe COVID-19 symptoms; rather, they tested positive for SARS-CoV-2 infection with a mild clinical course and no lung involvement.

Evidence supporting an inflammatory state in infected people experiencing mild symptoms could still explain the endothelial injury and hypercoagulable state of the patients in the case reports described.

Moreover, studies have been carried out to investigate the potential impact of immunological responses secondary to an exaggerated response to COVID-19 infection, such as hypoxia, oxidative stress, and excessive platelet-induced aggregation on the brain.

Unfortunately, there have been many delays in the diagnosis pathway throughout the pandemic, and treatment for AIS has been reported in COVID-19 positive patients, leading to increased disability.

Critically ill patients sedated for long periods due to the necessity of mechanical ventilation may likewise make it harder for clinicians to recognize a neurological deficit due to ischemic stroke. For this reason, clinical evaluation should be performed as soon as possible (for instance, periodic lightening of sedation, if possible) in conjunction with multimodal neuromonitoring (TCCD, processed electroencephalogram, near-infrared spectroscopy).

Intracranial hemorrhage (ICH) is less frequent than ischemic strokes in COVID-19 patients. However, ICH is associated with a high mortality rate.

At the beginning of the pandemic, an intriguing question was posed by Sharifi-Razavi and colleagues as to whether COVID-19 infection and ICH were coincidental or linked by a causative relationship.

In fact, COVID-19 infection is not an immediate cause of ICH unless the patient is undergoing anticoagulation treatment – a recognized risk factor for ICH in SARS-CoV2 infected patients.

Microscopic studies have demonstrated that viral inclusion is present within the endothelium of the vascular bed, leading to endotheliitis, loss of barrier function, mononuclear infiltration with subsequent disruption of the vascular wall, and finally hemorrhage.

It is also possible that hypercytokinemia induces an activation of the matrix metalloproteinases (MMPs) through IL-1, IL-6, TNF-α – a group of proteolytic enzymes that disrupt the vessel walls, which may increase the risk of rupture with consequent bleeding. Finally, a hypercoagulation state may also produce thrombotic microangiopathy of the vasa-vasorum with arterial wall hypoxia, vascular loss of tightness, and rupture.

Patients experiencing ICH have poor outcomes, with the literature reporting a mortality rate in up to 50% of cases.

Reversal of anticoagulation and pressure control are known factors affecting the outcomes of patients with ICH. These measures are hence strongly recommended for these patients. Critically ill COVID-19 patients also develop severe hypoxemia, an aggravating feature for those experiencing ICH.

The literature contains very few SAH case reports of COVID-19 patients, and it remains to be clarified as to whether viral infection may cause SAH.

Whether COVID-19 patients suffering from any form of stroke are at increased risk of severe sequelae or death compared to patients testing negative for COVID-19 is a matter of debate.
Compared with non-COVID-19 patients, those with AIS and COVID-19 infection had a higher mortality in a recent large prospective observational study. These results are in line with the abundance of existing data that uniquely demonstrate that COVID-19-positive patients suffering from AIS have worse outcomes than uninfected patients.

In summary, severe stroke among COVID-19 patients suggests that COVID-19 infection in itself – either mild or severe – plays an important role in triggering the sequence of events leading to cerebral vascular damage.

In summary, severe stroke among COVID-19 patients has different features including thrombosis of the arterial or venous cerebral compartment, primary ICH, and hemorrhagic transformation from ischemic lesion (Fig. 6).

Given that COVID-19 is still present worldwide, it should perhaps be included in the differential diagnosis of severe acute stroke patients admitted to the ICU, as well as in COVID-19 patients experiencing mild symptoms with a resolved viral infection and who present with neurological signs.

Ethical approval

The study was approved by the the Regional Ethics Committee (Comitato Etico Unico Regionale of Friuli Venezia Giulia Region). All clinical practices and observations were conducted in accordance with the Declaration of Helsinki.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Patient consent

Informed consent was obtained from patients for publication of this manuscript.

Consent for publication

All the authors have consented for publication of this manuscript.

References

[1] https://www.reuters.com/world/europe/france-experiencing-start-fifth-wave-covid-epidemic-minister-2021-11-10/ (last accessed 14 November 2021).
[2] Deana C, Rovida S, Orso D, et al. Learning from the Italian experience during COVID-19 pandemic waves: be prepared and mind some crucial aspects. Acta Biomed. 2021 May 12;92(2):e2021097.
[3] https://healthmanagement.org/icu/issue/article/shortage-of-icu-beds-leads-to-patients-death (last accessed 14 November 2021)
[4] Deana C, Verriello L, Pauletto G, et al. Insights into neurological dysfunction of critically ill COVID-19 patients. Trends Anesthesia Crit Care. 2021;36:30–38.
[5] Tang L, Zhao XM, Yu XY. Team management in critical care units for patients with COVID-19: an experience from Hunan Province, China. Crit Care. 2020;24:304.
[6] Mao L, Lin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683–690.
[7] Bruce SS, Kahan J, Hug T, et al. Missed cerebrovascular events during prolonged sedation for COVID-19 pneumonia. J Clin Neurosci. 2021;36:180–183.
[8] Xi Q, Kerth KA, Huang JL. COVID-19 stroke: a review. Brain Hemorrhages. 2021 Jun;2(2):76-83. doi: 10.1016/j.bhem.2020.11.001. Epub 2020 Nov 17. PMID: 33224751; PMCID: PMC7670261.
[9] Fara MG, Stein IK, Sklir M, et al. Macrothrombosis and stroke in patients with mild COVID-19 infection. J Thromb Haemost. 2020;18(8):2031–2033.
[10] Nannoni S, De Groot R, Bell S, et al. Stroke in COVID-19: A systematic review and meta-analysis. Int J Stroke. 2021 Feb;16(2):137–149. doi: 10.1177/1747493620972922. Epub 2020 Nov 11. PMID: 33103610; PMCID: PMC7859578.
[11] Qureshi AI, Baskett WJ, Huang W, et al. Acute Ischemic Stroke and COVID-19: An Analysis of 27,676 Patients. Stroke. 2021 Mar 32(2):905-912. doi: 10.1161/STROKEAHA.120.031786. Epub 2021 Feb 4. PMID: 33535779; PMCID: PMC7903982.
[12] Wang Z, Yang Y, Liang X, et al. COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management. Front Neurol. 2020 Oct;11:571996.
[13] Anipindi M, Scott A, Joyce L, et al. Case Report: Cerebral Venous Sinus Thrombosis and COVID-19 Infection. Front Med (Lausanne). 2021 Oct;15 (8):741594.
[14] Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;200:152–160.
[15] Song G, Zhang C, Isselbacher B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021 Mar 1;218(3):e2022135.
[16] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[17] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[18] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[19] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[20] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[21] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[22] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[23] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[24] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[25] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[26] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[27] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[28] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[29] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[30] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
[31] Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021 Mar;13(3):202–206.
10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21. PMID: 32325026; PMCID: PMC7172722.

[24]. Wijeratne T, Gillard C, Shahani M, El Naamani K, et al. COVID-19 Pathophysiology Predicts That Ischemic Stroke Occurrence Is an Expectation, Not an Exception. A Systematic Review. Front Neurol. 2021 Jan;12:1070221.

[25]. Gu S, Dai Z, Chen J, et al. Delayed Stroke Treatment during COVID-19 Pandemic in China. Cerebrovasc Dis. 2021 Jul 9;1-7. doi: 10.1159/000517075. Epub ahead of print. PMID: 34247153; PMCID: PMC8339026.

[26]. Battaglini D, Sauter M, Antonopoulos AS, et al. Neurological Complications and Noninvasive Multimodal Neuroimaging in Critically Ill Mechanically Ventilated COVID-19 Patients. Front Neurol. 2020 Nov;27(11).

[27]. Deana C, Vetrugno L, Bove T, De Monte A. Imagine a Giant Aneurysm in the Posterior Cerebral Artery: More Ultrasound Than Words. J Ultrasound Med. 2021 Mar;40(3):637-638.

[28]. Abbas R, El Naamani K, Shabani M, et al. Intracranial Hemorrhage in Patients with Coronavirus Disease 2019 (COVID-19): A Case Series. World Neurosurg. 2021 Oct;154:e473-e480. doi: 10.1016/j.wneu.2021.07.067. Epub 2021 Jul 21. PMID: 34298138; PMCID: PMC8294594.

[29]. Sharifi-Razavi A, Karimi N, Rezai N. COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect. 2020 Mar;27:35.

[30]. Cheruiyot I, Sehmi P, Ominde B, et al. Intracranial hemorrhage in coronavirus disease 2019 (COVID-19) patients. Neuro Sci. 2021 Jan;42(1):25-33. doi: 10.1007/s10072-020-04870-z. Epub 2020 Nov 3. PMID: 33140308; PMCID: PMC7605899.

[31]. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21. PMID: 32437596; PMCID: PMC7412750.

[32]. QUINAGLIA T, SHABANI M, BREDER I, et al. Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. Atherosclerosis. 2021 Apr;322:39-50. doi: 10.1016/j.atherosclerosis.2021.02.009. Epub 2021 Feb 15. PMID: 33706822; PMCID: PMC7883684.

[33]. SHAFI H, KHALESSI AA, KLUCHEL K, et.al. COVID-19: Association or coincidence? Medicine (Baltimore). 2020 Dec 18;99(51):e23862.

[34]. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINIT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of Neurointerventional Surgery (SNIS), and World Stroke Organization (WSO). Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, Shazam Hussain M, Jansen O, Jayaraman MV, Khalessi AA, Kluczel K, Blower SW, Lavine S, Meyers PM, Ramee S, Rüfenacht DA, Scimemi I, Towbridge D, Wolf D, Wolpert D, Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13 (6):612-632. doi: 10.1177/1747493018778713. Epub 2018 May 22. PMID: 29786478.

[35]. SHI L, XU S, ZHENG J, et al. Blood Pressure Management for Acute Intracerebral Hemorrhage: A Meta-Analysis. Sci Rep. 2017 Oct 30;7(1):14345.

[36]. Ferdinand P, Rolle C. Hypoxia after stroke: a review of experimental and clinical evidence. Exp Stroke Med. 2016;8:9.

[37]. CEZAR JUNIOR AB, FAQUINI IV, SILVA JIL, et al. Subarachnoid hemorrhage and COVID-19: Association or coincidence? Medicine (Baltimore). 2020 Dec 18;99(51):e23862.

[38]. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINIT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of Neurointerventional Surgery (SNIS), and World Stroke Organization (WSO). Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, Shazam Hussain M, Jansen O, Jayaraman MV, Khalessi AA, Kluczel K, Blower SW, Lavine S, Meyers PM, Ramee S, Rüfenacht DA, Schirmer CM, Towbridge D, Wolf D, Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13 (6):612-632. doi: 10.1177/1747493018778713. Epub 2018 May 22. PMID: 29786478.

[39]. Qureshi AI, Baskett W, Huang W, et al. Subarachnoid Hemorrhage and COVID-19: An Analysis of 282,718 Patients. World Neurosurg. 2021 Jul;151:e615-e620. doi: 10.1016/j.wneu.2021.04.089. Epub 2021 Apr 30. PMID: 33940263; PMCID: PMC8086384.

[40]. Marti-Fárbregas J, Gúasido-Alonso D, Delgado-Mederos R, et al. COVICTUS Collaborators. Impact of COVID-19 Infection on the Outcome of Patients With Ischemic Stroke. Stroke. 2021 Dec;52(12):3908-3917. doi: 10.1161/STROKEAHA.121.034883. Epub 2021 Aug 30. PMID: 34455823; PMCID: PMC81607902.